Delmedica Investments

Delmedica Investments is a biotechnology and medical device company specializing in regenerative medicine and orthobiologics. The company's flagship technology, the Xerthra system, is a point-of-care medical device designed to produce autologous conditioned serum (ACS) and platelet-rich plasma (PRP) with high concentrations of anti-inflammatory cytokines. These therapies are primarily utilized to treat musculoskeletal conditions such as osteoarthritis and sports-related injuries by leveraging the patient's own biological factors to reduce inflammation and promote tissue repair. Delmedica operates internationally, providing clinicians with advanced tools for personalized biological treatments in orthopedics and rheumatology.